Boehringer, Bayer Kinase Inhibitors Offer Oral Option In HER2-Mutated Lung Cancer
Both Drugs In Phase III First-Line Trials
Boehringer presented Phase Ib results for zongertinib and Bayer presented Phase I/II results for BAY 2927088 in NSCLC with HER2 mutations – a rare cancer with ADC Enhertu as a major competitor – at the WCLC meeting.
